期刊名称：CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION ISSN： 1055-9965 版本： SCI-CDE 出版频率： Monthly 出版社： AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404   出版社网址： http://www.aacr.org/ 期刊网址： http://cebp.aacrjournals.org/ 影响因子： 4.254 主题范畴： ONCOLOGY;    PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Cancer Epidemiology, Biomarkers & Prevention (ISSN 1055-9965) is published monthly, one volume/year, by the American Association for Cancer Research, Inc. (AACR), 615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404. Telephone: (215) 440-9300; Fax (215) 440-9354; E-mail: cebp@aacr.org. Scope: Cancer Epidemiology, Biomarkers & Prevention publishes original, peer-reviewed research on cancer causation, mechanisms of carcinogenesis, prevention, and survivorship. Topics include descriptive, analytical, biochemical, and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention. All submissions undergo peer review. Cancer Epidemiology, Biomarkers & Prevention is abstracted or indexed in BIOSIS Previews? Chemical Abstracts, Current Contents/CM? Index Medicus, and MEDLINE. The journal is printed on acid-free paper in the U.S.A. Address editorial correspondence to: John D. Potter, M.D., Ph.D. and David S. Alberts, M.D., Co-Editors-in-Chief, Cancer Epidemiology, Biomarkers & Prevention, c/o AACR Publications Dept., 615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404. Telephone: (215) 440-9300; Fax (215) 440-9354; E-mail: cebp@aacr.org. See Instructions for Authors for manuscript submission information. Subscriptions: For subscription information, click here. Back Issues and Single Copy Sales: Copies of back stock of the journal Cancer Epidemiology, Biomarkers & Prevention may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Telephone: (800) 633-4931; (205) 995-1567 outside U.S. Fax: (205) 995-1588. As long as supplies permit, single copies of Cancer Epidemiology, Biomarkers & Prevention will be sold at $25 per copy, plus $3 shipping for orders outside the U.S. Advertising representative: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009. Telephone: (856) 768-9360. Fax: (856) 753-0064. Advertisement insertion orders and copy must be received 1 month prior to the date of the issue in which the advertisement is to be published. The journal is mailed by approximately the 7th day of the month of issue. Instructions to Authors Scope Cancer Epidemiology, Biomarkers & Prevention (CEBP) publishes original research on cancer causation, mechanisms of carcinogenesis, prevention, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention. Particular attention will be given to the identification of factors associated with various aspects of the carcinogenic process, including genetic susceptibility, host factors, infectious agents, chemical and physical carcinogens, environmental contaminants, dietary components and behavioral factors such as tobacco use and sun exposure. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, the Editors encourage the submission of manuscripts with an interdisciplinary approach. Editorial Policy When a manuscript is received for consideration, the Editors assume that all authors have agreed to its submission and that no similar paper has been or will be submitted for publication elsewhere. Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the publisher and copyright owner of the journal, prior to publication. Once an article is accepted for publication in Cancer Epidemiology, Biomarkers & Prevention the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the World Medical Association, Bôite Postale 63, 01212, Ferney-Voltaire Cedex, France. Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal to the Editor-in-Chief any relationships that they believe could be construed as causing a conflict of interest with regard to the manuscript submitted for review. Publication Categories Descriptions of the types of articles considered for publication (and page limits, if any) are listed below. [Note: A single published page is approximately equal to 1000 words of text, 50 references, or 4 tables or figures of average size.] Original Research Paper Research Articles.Manuscripts that report original studies in epidemiology, biomarkers, prevention, or behavioral sciences relating to cancer which are well-documented, novel, and of high scientific merit. Most manuscripts will be published within 8 weeks of acceptance. Short Communication. Original research articles of scientific merit that are limited in scope; short communications should be no more than 4 published pages in length. Null Results in Brief. Original reports of null results of important a priori hypotheses tested with sufficient statistical power. These brief reports should be no more than 1 published page in length and must follow the specified format exactly. Please indicate in your covering letter that your submission is for the Null Results category. Note that authors of submissions to the Null Results in Brief category will be permitted to make only minor revisions; submissions that require substantive revisions will not be accepted. In addition, reviewers' comments may not be provided to authors of rejected manuscripts.   Special Articles Letters to the Editor. Readers are welcome to submit comments on articles recently published in the journal. Letters should be no more than 1 published page in length. Reviews and Minireviews. Reviews and minireviews on timely subjects of interest and importance to the readers of CEBP are welcome. Unsolicited reviews will be considered for publication, and others will be invited by the Editor. Reviews should be no more than 10 published pages in length. Minireviews are more focused articles and should be no more than 5 published pages in length. Meeting Reports. Reports on relevant symposia and conferences should include a statement of purpose, a summary of the findings presented, and recommendations for future research. Meeting reports should be no more than 5 published pages in length. Hypotheses/Commentaries. Creative new insights or commentaries that present original ideas relating to cancer causes and prevention. Hypotheses and Commentaries should be no more than 4 published pages in length. Global Perspectives. Summaries of current national research programs which increase international awareness within the scientific community are welcome. These summaries should be no more than 5 published pages in length. Invited Articles Editorials. Brief papers commenting on articles in the journal. Point-Counterpoint. Articles featuring two or more experts in a particular field who present counter-balancing views on a topic of interest to the readership. News. Information of interest to the readers of CEBP, such as public issues, funding for cancer research, public education, science education, training opportunities in the field, etc. Priority Publication The standard time from final acceptance to publication is approximately 8 weeks. However, outstanding manuscripts will be placed on an accelerated Priority Publication schedule, reducing the publication time for these papers to 4-5 weeks. Priority Publication status is assigned at the discretion of the Senior Editors and applies only to manuscripts that require minor modifications. Revisions of Priority Publication manuscripts should be returned to the AACR Publications Office by express mail within one week of notification. Manuscript Submission CEBP is now accepting manuscript submissions online. The AACR Online Manuscript Submission System is available at www.rapidreview.com/AACR2/author.html. Authors are expected submit their manuscripts online. Authors that cannot submit their files online will be asked to fill out the online submission form and either e-mail their manuscript files or mail hard copy manuscripts to the Editorial Office for uploading. For hard copy submissions, mail four copies of manuscripts to Cancer Epidemiology, Biomarkers & Prevention, AACR Publications Department, 615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. If study subjects or methods are more fully described elsewhere, please provide reprints. In order to expedite the review process, authors must indicate in a cover letter the specialty area of the paper. Specialty areas are as follows: Epidemiology Molecular Epidemiology Genetic Epidemiology Biomarkers in Prevention Nutrition in Prevention Screening and Early Detection Behavior in Prevention Chemoprevention Survivorship and Supportive Care Methods and New Models Fax transmission and overnight delivery service will be used to expedite review and publication. Format Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows: 1. Title page, including title, authors, and affiliations; 2. A running title of fewer than 50 characters; 3. Text, arranged in this order: Abstract (not more than 250 words of running text, to include objective, method, results, and conclusion), Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References; 4. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals; 5. Tables, on a page separate from the text, with descriptive titles and/or legends; 6. Figure legends, on pages separate from the text. Define all symbols and include staining for halftones, where applicable. The format for Null Results in Brief articles is as follows: 1. A title that communicates the null result; 2. A concise introduction; 3. A hypothesis in 1 or 2 sentences; 4. Materials and methods; 5. Results; 6. A statement of statistical power; 7. A description of the study's limitations; 8. Conclusions; 9. Only 1 small figure or table; 10. References (approximately 5). References Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permissions. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced. Sample references: 1. Fontham E. T. H., Correa, P., Wu-Williams, A., Reynolds, P., Greenberg, R. S., Buffler, P. A., Chen, V. W., Boyd, P. Alterman, T., Austin, D. F., Liff, J., and Greenberg, S. D. Lung cancer in nonsmoking women: A multicenter case-control study. Cancer Epidemiol., Biomark. Prev., 1: 35-43, 1991. 2. Reznikoff, C. A., Swaminathan, S., and Verma, A. K. Cultured normal human uroepithelial cells: a new system for in vitro carcinogenesis studies. In: M. Webber and L. Sikeley (eds.), In Vitro Models for Cancer Research pp. 63-101. Boca Raton. FL: CRC Press, 1986. Illustrations Provide four original sets of illustrations (whether line-cut drawings or halftones). Label each figure in pencil on the reverse side with the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on illustrations should not be smaller than 6-point or larger than 12-point type. All illustrations will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is $750 per color figure. Submit color illustrations on flexible backing. Typesetting Manuscripts from Computer Disks Cancer Epidemiology, Biomarkers & Prevention requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission and a form which must be completed and returned with your disk to the AACR Publications Department within 48 hours of notification of acceptance. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript. Proofs Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors' corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive changes in proof. Publication Fees A page charge of $50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (address below) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges. "Disk Submission Form" in PDF format Download Adobe Acrobat Reader 4.0 For More Information, Contact: American Association for Cancer Research, Publications Department, 615 Editorial Board Co-Editors-in-Chief John D. Potter, M.D., Ph.D. Fred Hutchinson Cancer Research Center Division of Public Health Sciences 1100 Fairview Avenue, N., MP 702 P.O. Box 19024 Seattle, WA 98109-1024 Phone: 206-667-4683 E-mail: jpotter@fhcrc.org David S. Alberts, M.D. Arizona Cancer Center University of Arizona College of Medicine P.O. Box 245024 1515 North Campbell Avenue Tucson, AZ 85724-5024 Phone: 520-626-7685 E-mail: dalberts@azcc.arizona.edu   Senior Editors Epidemiology Dr. Louise Brinton National Institutes of Health 6120 Executive Plaza Blvd. Building Executive Plaza South Room 7068 Rockville, MD 20852-7234 Phone: 301-496-1693 E-mail: brintonl@exchange.nih.gov Dr. Adele Green Queensland Institute of Medical Research Royal Brisbane Hospital Herston, QLD 4029 Australia Phone: 61-7-3362-0366 E-mail: adeleg@qimr.edu.au Genetic Epidemiology Dr. Thomas A. Sellers Mayo Clinic Cancer Center 200 First Street, S.W. Rochester, MN 55905 Phone: 507-284-5535 E-mail: sellers.thomas@mayo.edu Dr. Robert W. Haile Genetic Epidemiology Program University of Southern California Keck School of Medicine 1141 Eastlake Avenue Los Angeles, CA 90089-9175 Phone: 323-865-0495 E-mail: haile@hsc.usc.edu Nutrition in Prevention Dr. Johanna Wyss Lampe Cancer Prevention Fred Hutchinson Cancer Research Center MP900 P.O. Box 19024 1100 Fairview Avenue, N. Seattle, WA 98109-1024 Phone: 206-667-6580 E-mail: jlampe@fhcrc.org Dr. Elio Riboli Unit of Nutrition and Cancer Unit of Analytical Epidemiology International Agency for Research on Cancer 150, Cours Albert Thomas 69372 Lyon, Cedex 08 France Phone: 33-47-273-8411 E-mail: riboli@iarc.fr Chemoprevention Dr. Ernest T. Hawk Gastrointestinal and Other Cancer Research Group NCI-DCP EPN Suite 2141 MSC 7317 6130 Executive Blvd. Bethesda, MD 20892-7317 Phone: 301-594-2684 E-mail: eh51p@nih.gov Survivorship and Supportive Care Dr. Leslie L. Robison Division of Pediatric Epidemiology University of Minnesota MMC 422 Minneapolis, MN 55455 Phone: 612-626-2902 E-mail: robison@epivax.epi.umn.edu  Molecular Epidemiology Dr. Maria Ellen Martinez University of Arizona Arizona Cancer Center 1515 North Campbell Tucson, AZ 85724 Phone: 520-626-8130 E-mail: emartinez@azcc.arizona.edu Dr. Christopher Paul Wild Molecular Epidemiology Unit Research School of Medicine University of Leeds Algernon Firth Bldg., 3rd FL Leeds, W. Yorkshire LS2 9JT England Phone: 44-113-233-6602 E-mail: c.p.wild@leeds.ac.uk Biomarkers in Prevention Dr. Dean E. Brenner Internal Medicine University of Michigan Medical Center 2150 Cancer & Geriatric Center 1500 East Hospital Drive Ann Arbor, MI 48109-0934 Phone: 734-647-1417 E-mail: dbrenner@umich.edu Dr. Powel H. Brown Baylor College of Medicine BCM 600 One Baylor Plaza Houston, TX 77030 Phone: 713-798-1609 E-mail: pbrown@breastcenter.tmc.edu Screening and Early Detection Dr. Emanuel Frank Petricoin III FDA-NCI Clinical Proteomics Program Food & Drug Administration Building 29A, Room 2B02 8800 Rockville Pike Bethesda, MD 20892 Phone: 301-827-1753 E-mail: petricoin@cber.fda.gov Behavior in Prevention Dr. Ellen R. Gritz Department of Behavioral Science UT M. D. Anderson Cancer Center Box 243 1515 Holcombe Boulevard Houston, TX 77030 Phone: 713-745-3187 E-mail: egritz@mdanderson.org Dr. Sally W. Vernon Epidemiology & Behavioral Sciences UT Houston School of Public Health Suite 2560 7000 Fannin Houston, TX 77030 Phone: 713-500-9760 E-mail: svernon@sph.uth.tmc.edu Methods and New Models Dr. Margaret Pepe Fred Hutchinson Cancer Research Center Public Health Sciences Division 1100 Fairview Avenue, N. P.O. Box 19024 Seattle, WA 98109 Phone: 206-616-9316 E-mail: mspepe@u.washington.edu   Editorial Office American Association for Cancer Research Publications Department 615 Chestnut Street 17th Floor Philadelphia, PA 19106-4404 (215) 440-9300 (215) 440-9355